Published in The New England Journal of Medicine. Peer-reviewed. Large sample size. Sound methodology. A daily pill DOUBLED survival time for patients with an advanced and aggressive form of pancreatic cancer when compared to chemotherapy. Daraxonrasib works by locking onto the mutated KRAS gene.
www.sciencenews.org
Daraxonrasib, which nearly doubled patients' survival time, fights the disease in a new way. It bear-hugs a cancer protein that drives cell growth.
